Key result
An oral GLP-1 pill and semaglutide with amylin were among the emerging diabetes treatments highlighted in an expert interview discussing key research from the ADA 2026 Scientific Sessions.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This Medical News article provides an interview discussing new diabetes research presented at the American Diabetes Association's annual Scientific Sessions.
This Medical News article is an interview with Rita Kalyani, MD, MHS, the American Diabetes Association’s chief scientific and medical officer and a professor of medicine at Johns Hopkins University School of Medicine, about research presented at the organization’s annual Scientific Sessions.
No takes yet. Share an insight, caveat, or question.
Jennifer Abbasi (2026) studied this question. An oral GLP-1 pill and semaglutide with amylin were among the emerging diabetes treatments highlighted in an expert interview discussing key research from the ADA 2026 Scientific Sessions.
Synapse has enriched 10 related papers. Consider them for comparative context: